Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study

Antti Turunen1,2 | Raija Silvennoinen1,3 | Anu Partanen1 | Jaakko Valtola1 | Timo Siitonen4 | Mervi Putkonen5 | Marja Sankelo6 | Marja Pyörälä1 | Taru Kuittinen1 | Karri Penttilä7,8 | Anu Sikiö9 | Eeva-Riitta Savolainen10 | Pentti Mäntymaa11 | Jukka Pelkonen11,12 | Ville Varmavuo13 | Esa Jantunen1,2,14

1Department of Medicine, Kuopio University Hospital, Kuopio, Finland
2Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
3Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
4Department of Medicine, Oulu University Hospital, Oulu, Finland
5Department of Medicine, Turku University Hospital, Turku, Finland
6Department of Internal Medicine, Tampere University Hospital, Tampere, Finland
7Finnish Medicines Agency, Kuopio, Finland
8Department of Medicine, Savonlinna Central Hospital, Savonlinna, Finland
9Department of Medicine, Central Hospital of Central Finland, Jyväskylä, Finland
10Nordlab, Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland
11Laboratory Centre of Eastern Finland, Kuopio, Finland
12Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland
13Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland
14Department of Medicine, North Carelia Hospital District, Joensuu, Finland

Correspondence
Antti Turunen, Department of Medicine, Kuopio University Hospital, P.O. Box 100, Kuopio, 70029 KYS, Finland.
Email: antti.turunen@fimnet.fi

Funding information
Cancer Fund of North Savo; North Savo Hospital District EVO Fund; North Savo Hospital District Research Fund; North Savo Hospital District VTR Fund; The Finnish Medical Foundation; The Finnish Society of Hematology; Blood Disease Research Foundation; Sanofi Genzyme

Abstract

Background: Autologous stem cell transplantation (auto-SCT) is a widely used treatment option in multiple myeloma (MM) patients. The optimal graft cellular composition is not known.

Study design and methods: Autograft cellular composition was analyzed after freezing by flow cytometry in 127 MM patients participating in a prospective multicenter study. The impact of graft cellular composition on hematologic recovery and outcome after auto-SCT was evaluated.

Results: A higher graft CD34+ cell content predicted faster platelet recovery after auto-SCT in both the short and long term. In patients with standard-risk
cytogenetics, a higher graft CD34+ count (>2.5 × 10^6/kg) was linked with shorter progression-free survival (PFS; 28 vs. 46 months, \( p = 0.04 \)), but there was no difference in overall survival (OS) \( (p = 0.53) \). In a multivariate model, a higher graft CD34+CD133+CD38− (>0.065 × 10^6/kg, \( p = 0.009 \)) and NK cell count (>2.5 × 10^6/kg, \( p = 0.026 \)), lenalidomide maintenance and standard-risk cytogenetics predicted better PFS. In contrast, a higher CD34+ count (>2.5 × 10^6/kg, \( p = 0.015 \)) predicted worse PFS. A very low CD3+ cell count (<20 × 10^6/kg, \( p = 0.001 \)) in the infused graft and high-risk cytogenetics remained predictive of worse OS.

**Conclusions:** Autograft cellular composition may impact outcome in MM patients after auto-SCT. More studies are needed to define optimal graft composition.

**KEYWORDS**
autograft cellular composition, autologous stem cell transplantation, CD34+ cells, hematologic recovery, myeloma, NK cells, outcome, T lymphocytes

---

## 1 | INTRODUCTION

Multiple myeloma (MM) is the leading indication for autologous stem cell transplantation (auto-SCT) according to the European Group for Blood and Marrow Transplantation registry, which had over 12,000 transplants for MM reported in 2018.1 High-dose chemotherapy (HDT) followed by auto-SCT after first-line therapy in eligible patients has been proven to prolong progression-free survival (PFS) in newly diagnosed MM patients also in the era of novel drugs.2-4

Several factors, including patient characteristics, previous therapy, and the mobilization method used, influence graft cellular composition. The use of lenalidomide prior to graft collection may hamper stem cell mobilization.5,6 Mobilization with cyclophosphamide (CY) and granulocyte colony-stimulating factor (G-CSF) results in higher CD34+ yields than mobilization with G-CSF alone.7,8 The addition of CY in the mobilization alters graft cellular composition by decreasing the number of more primitive CD34−CD133+CD38− cells, NK cells, and other lymphocytes.9 In contrast, the use of plerixafor (PLER) in poorly mobilizing patients seems to increase the B and T lymphocyte, NK cell, and CD34+CD133+CD38− counts in the grafts.10

The CD34+ cell count has remained the most important marker of graft quality in the autologous setting. There are also some retrospective data supporting improved PFS and overall survival (OS) in patients with higher graft CD34+ cell doses.11 A higher number of lymphocytes in the infused blood grafts have been linked with better PFS and OS in MM patients.12,13 Also a higher graft CD3+CD4+ count has been associated with better outcome.14 Data regarding graft NK cells and their role in post-transplant recovery in MM patients are limited. However, faster blood NK cell count recovery has been linked with improved outcome.15

The aim of the prospective multicenter Graft and Outcome in Autologous stem cell transplantation (GOA) study is to investigate the effects of different mobilization methods on collected blood graft cellular composition and to evaluate the effects of infused graft composition on hematological and immunological recovery and PFS and OS post-transplant. In this study, we analyzed the influence of graft cellular composition on recovery of blood counts and post-transplant outcome in MM patients.

## 2 | PATIENTS AND METHODS

### 2.1 | Patients

Altogether 147 MM patients were included in the prospective non-interventional multicenter GOA study. Graft composition data were available in 127 patients and these patients were included in the present study. The patients received their first auto-SCT between May 2012 and December 2016 at four university hospitals (Kuopio, Oulu, Tampere, and Turku) in Finland. A proportion of the patients \((n = 36, 28\%)\) participated also in the MM-02 study (NCT01790737) conducted by the Finnish Myeloma Group.16,17

The patient characteristics are presented in Table 1. The median time from MM diagnosis to the initiation of stem cell mobilization was 4 months (range 2–65). High-risk cytogenetics were defined by FISH panels according to the revised International Staging System as deletion 17p and/or translocation (4;14) and/or t(14;16).18


### TABLE 1  Patient characteristics

| Variable                        | n = 127 |
|---------------------------------|---------|
| Sex (male/female)               | 64/63   |
| Age: median (range)             | 64 (49–73) |
| Paraprotein type                |         |
| IgG                             | 73 (58%) |
| IgA                             | 28 (22%) |
| Light chain                     | 25 (20%) |
| IgM                             | 1 (1%)  |
| Cytogenetics at diagnosis       |         |
| Standard risk                   | 95 (75%) |
| High risk<sup>a</sup>           | 22 (17%) |
| Unknown                         | 10 (8%)  |
| First-line induction therapy<sup>b</sup> |         |
| VCD                             | 44 (35%) |
| VRD                             | 40 (32%) |
| VD                              | 38 (30%) |
| Other<sup>c</sup>               | 5 (4%)   |
| Mobilization                    |         |
| Cyclophosphamide + G-CSF        | 73 (58%) |
| G-CSF alone                     | 54 (43%) |
| Use of plerixafor               | 16 (13%) |
| Disease status at auto-SCT      |         |
| sCR                             | 4 (3%)   |
| CR                              | 21 (17%) |
| VGPR                            | 58 (46%) |
| PR                              | 40 (32%) |
| SD                              | 1 (1%)   |
| PD                              | 3 (2%)   |
| Disease status 3 months after auto-SCT |         |
| sCR                             | 12 (9%)  |
| CR                              | 41 (32%) |
| VGPR                            | 54 (43%) |
| PR                              | 14 (11%) |
| SD                              | 3 (2%)   |
| PD                              | 3 (2%)   |

Note: VCD, bortezomib–cyclophosphamide–dexamethasone; VD, bortezomib–dexamethasone; VRD, bortezomib–lenalidomide–dexamethasone.

Abbreviations: G-CSF, granulocyte colony-stimulating factor; auto-SCT, autologous stem cell transplantation.

<sup>a</sup>Defined as either any percentage of del(17p) and/or translocation t(4;14) and/or t(14;16).

<sup>b</sup>Twenty-four patients (19%) received > 1 lines of myeloma therapy before stem cell collection.

<sup>c</sup>Bortezomib–melphalan–prednisolone (VMP) in two patients, lenalidomide–dexamethasone (RD) in two patients (2%), and bortezomib–thalidomide–dexamethasone in one patient (1%).

### 2.2  Mobilization and collection of blood grafts

Seventy-three patients (57%) were mobilized with low-dose (2 g/m<sup>2</sup>) cyclophosphamide (LD-CY) + G-CSF, whereas 54 patients (43%) received only daily filgrastim of 10 μg/kg for mobilization (Table S1). The G-CSF used was either filgrastim of 5 μg/kg per day until the completion of graft collection (n = 53, 73%) or a single pegfilgrastim of 6 mg injection (n = 20, 27%) in chemomobilized patients. The G-CSF mobilized patients received filgrastim of 10 μg/kg daily until the completion of cell apheresis. The subgroup of patients participating in the MM02 trial received mobilization with either LD-CY plus filgrastim or filgrastim alone in a randomized fashion after three cycles of induction treatment with bortezomib, lenalidomide and dexamethasone (VRD) followed by a single auto-SCT and lenalidomide maintenance.<sup>16,17</sup> The blood CD34<sup>+</sup> (B-CD34<sup>+</sup>) level was determined daily during the stem cell collection period by flow cytometry using an ISHAGE protocol<sup>19</sup> at the stem cell laboratories of each participating university hospital.

A minimum collection target of 2.0 × 10<sup>6</sup>/kg CD34<sup>+</sup> cells was used for a single transplant. The patients participating in the MM-02 study had a higher minimum collection target of 3.0 × 10<sup>6</sup>/kg CD34<sup>+</sup> cells for a single transplant and 6.0 × 10<sup>6</sup>/kg if a second transplant was considered feasible. PLER was added to the mobilization in 16 patients (13%). PLER was administered either preemptively in case of inadequate mobilization or after failing to reach sufficient CD34<sup>+</sup>yields with declining B-CD34<sup>+</sup>counts.<sup>20</sup>

Oulu and Tampere University Hospitals used the Spectra Optia Apheresis device (Software 7.2, Terumo BCT) for blood graft collection throughout the study. In Kuopio University Hospital, a COBE Spectra AutoPBSC (Lakewood, CO) apheresis device was used initially, but from April 2013 onwards the Spectra Optia was used. Turku University Hospital used a different apheresis device (COM.TEC Fresenius blood cell separator, Fresenius Hemo Care GmbH). The blood volume circulated per apheresis was 2.3–3.0 times the estimated blood volume of the patient.

### 2.3  Graft analysis

Two 0.5 ml tubes were taken from each apheresis product for subsequent graft cellular composition analyses. Dimethyl sulfoxide was added to achieve a concentration of 10% in order to protect the cells. These specimens as
well as the graft bags were cryopreserved in a freezer with controlled-rate freezing in liquid nitrogen. The cryopreserved graft samples were delivered to the Department of Microbiology, University of Eastern Finland, for graft cellular composition analyses, which were performed by a single experienced flow cytometrist (A.R.). After thawing, the graft samples were analyzed using the FACSCanto (Becton Dickinson, San Jose, CA) flow cytometry system.20

### 2.4 High-dose therapy and post-transplant follow-up

High-dose melphalan of 200 mg/m² was given as HDT on day −2. The thawed blood grafts were infused on day 0. Ninety patients (71%) were given G-CSF post-transplant based on institutional preferences, of which 58 patients (64%) received filgrastim of 5 μg/kg daily until neutrophil engraftment, and 32 patients (36%) received a single 6 mg dose of pegfilgrastim.

Neutrophil and platelet (PLT) engraftment were defined as the first of three consecutive days with a blood neutrophil count >0.5 × 10⁹/L or a PLT count >20 × 10⁹/L without PLT infusions, respectively. The hematologic recovery was assessed by measuring complete blood count on day +15 and at 1, 3, 6, and 12 months after auto-SCT. The follow-up of hematological recovery was discontinued in case of disease progression and re-treatment. Thirty-six patients (28%) received lenalidomide maintenance after auto-SCT as a part of the MM-02 study.

### 2.5 Statistical analysis

SPSS Statistics version 25 (IBM Corporation, Armonk, NY) was used for statistical calculations. Continuous variables are presented with medians and ranges. The Mann–Whitney U-test and Pearson’s chi-square test were used to assess statistical significance. Receiver operating characteristic (ROC) analyses were used to find out optimal cutoff points for graft cellular components correlating with hematological recovery, PFS, and OS.

#### Table 2: Comparison of infused blood graft cellular composition according to the mobilization method in multiple myeloma patients

| Blood graft content (×10⁶ cells/kg) | Patients mobilized with CY + G-CSFᵃᵇ⁻, n = 73 | Patients mobilized with G + CSF aloneᵃᵇ⁻, n = 54 | p value |
|------------------------------------|------------------------------------------------|------------------------------------------------|---------|
| CD3⁴⁺ cells without 7-AAD          | 3.5 (1.6–8.7); 73                              | 2.6 (0.6–7.6); 54                              | <0.001  |
| CD3⁴⁺ cells with 7-AAD             | 2.8 (0.7–7.2); 73                              | 1.7 (0.2–4.6); 54                              | <0.001  |
| CD3⁴⁺CD133⁺CD38⁻ cells            | 0.07 (0.007–0.6); 73                           | 0.05 (0.005–0.17); 54                          | 0.016   |
| CD3⁺ cells                        | 41.3 (2.8–354.2); 72                           | 170 (19.6–1576.2); 53                          | <0.001  |
| CD3⁺CD4⁺ cells                    | 25.6 (2.1–290.3); 72                           | 102.2 (14.7–474.7); 53                          | <0.001  |
| CD3⁺CD8⁻ cells                    | 13.8 (0.8–90.7); 72                             | 76.6 (4.7–1213.9); 53                           | <0.001  |
| CD19⁺ cells                       | 0.9 (0.0–66.6); 72                              | 5.0 (0.0–61.6); 53                              | <0.001  |
| NK cells                           | 3.3 (0.2–35.5); 72                              | 25.7 (1.2–748.9); 53                            | <0.001  |

ᵃMeasured by flow cytometry after cryopreservation. Data are reported as median (range); number of observations.

ᵇMissing data. One patient from both groups with only CD3⁴⁺ analysis.

#### Table 3: Comparison of infused blood graft cellular composition according to use of plerixafor in multiple myeloma patients

| Blood graft content (×10⁶ cells/kg) | Patients mobilized without plerixaforᵃᵇ⁻, n = 111 | Patients mobilized with plerixaforᵃᵇ⁻, n = 16 | p value |
|------------------------------------|-------------------------------------------------|------------------------------------------------|---------|
| CD3⁴⁺ cells without 7-AAD          | 3.1 (0.6–8.7); 111                              | 3.0 (1.8–7.6); 16                               | 0.703   |
| CD3⁴⁺ cells with 7-AAD             | 2.4 (0.2–7.2); 111                              | 2.2 (1.2–4.6); 16                               | 0.549   |
| CD3⁴⁺CD133⁺CD38⁻ cells            | 0.06 (0.005–0.6); 111                           | 0.06 (0.013–0.3); 16                            | 0.799   |
| CD3⁺ cells                        | 65.7 (2.8–1576.2); 110                           | 247.4 (29.2–715.8); 15                           | 0.001   |
| CD3⁺CD4⁺ cells                    | 40.9 (2.1–368.4); 110                            | 136.8 (18.8–474.7); 15                           | <0.001  |
| CD3⁺CD8⁻ cells                    | 23.1 (0.8–1213.9); 110                           | 76.6 (10.6–250.1); 15                            | 0.007   |
| CD19⁺ cells                       | 1.4 (0.0–61.6); 110                              | 12.3 (0.6–66.6); 15                              | 0.001   |
| NK cells                           | 8.9 (0.2–748.9); 110                             | 27.0 (1.2–69.2); 15                              | 0.006   |

ᵃMeasured by flow cytometry after cryopreservation. Data are reported as median (range); number of observations.

ᵇMissing data. One patient from both groups with only CD3⁴⁺ analysis.
respectively. ROC curve cutoff points were optimized using Youden’s index. The continuous variables were transformed into categorical variables using either median or lower limit of reference values as a cutoff point to perform ROC analyses regarding hematological recovery. PFS was defined as time from auto-SCT to the first documentation of progressive disease or death.

Kaplan–Meier method and log-rank test were used for survival analyses. Cox regression model with categorical variables was applied for multivariate analyses. The results of the Cox regression model are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Two-tailed p values <0.05 were considered statistically significant. No adjustments for multiple comparisons were made.

2.6 | Ethics

The Ethics Committee of North Savo Hospital District provided approval to the GOA study (13/2012). All patients gave their written informed consent to participate in the study.

3 | RESULTS

3.1 | Graft cellular composition

The median graft CD34+ cell count measured before cryopreservation was 3.5 x 10⁶/kg (range 2.0–11.4). The viable CD34+ count (with 7-AAD) after thawing was 2.35 x 10⁶/kg (0.2–7.2). The median loss of CD34+ cells during cryopreservation was 34% (0–93). The infused grafts of LD-CY + G-CSF mobilized patients contained higher amounts of CD34+ and CD34+CD133+CD38− cells than those of G-CSF mobilized patients, but the CD3+, CD3+CD4+, CD3+CD8+, CD19+, and NK cell counts were significantly lower in the grafts of chemomobilized patients (Table 2). The use of PLER also significantly altered graft cellular composition, resulting in higher CD3+CD4+, CD3+CD8+, CD19+, and NK cell counts in the grafts (Table 3).

3.2 | Hematologic recovery after auto-SCT

The median time to PLT engraftment was 12 days (0–54) and the neutrophil engraftment was also reached in a median of 12 days (8–30). A higher infused graft CD34+ cell count (>2.0 x 10⁶/kg, n = 70) was associated with faster PLT engraftment (11 vs. 12 days, p = 0.019). In these patients, the PLT counts remained higher from 3 months after auto-SCT (199 vs. 171 x 10⁹/L, p = 0.017) until 1 year post-transplant (204 vs. 174 x 10⁹/L, p = 0.022). Neutrophil engraftment was not associated with the infused graft CD34+ cell count. More rapid PLT engraftment was linked with a higher graft CD33+ count (>40 x 10⁶/kg, n = 85; 11 vs. 13 days, p = 0.031) and lower NK cell count (<20 x 10⁶/kg, n = 87; 11 vs. 14 days, p = 0.009), which were also associated with slightly faster neutrophil engraftment (12 vs. 12 days, p = 0.043).

In multivariate analysis including the graft CD34+ (>2.0 x 10⁶/kg), CD3+ (>40 x 10⁶/kg) and NK cell (>20 x 10⁶/kg) counts, gender, age (>≤60 years), mobilization method used (LD-CY + G-CSF vs. G-CSF alone), the addition of PLER to the mobilization, and the use of G-CSF post-transplant, none of the abovementioned parameters significantly predicted faster PLT (<12 days) engraftment. NK cell count ≤20 x 10⁶/kg (HR 2.129, CI 1.117–4.055, p = 0.022) and the use of G-CSF post-transplant (HR 4.567, CI 1.945–10.723, p < 0.001) predicted faster neutrophil (<12 days) engraftment in multivariate model, respectively.

3.3 | Graft cellular composition and post-transplant survival

At the end of the follow-up in May 2020, the median follow-up for patients remaining alive was 68 months (35–89). Ninety patients (71%) had experienced a disease progression and 34 patients (27%) had died. All patients who had died during the follow-up had undergone MM progression. High-risk cytogenetics was associated with inferior PFS (12 vs. 31 months, p = 0.003) and OS (43 months vs. not reached, p < 0.001) compared to patients with standard risk (SR) cytogenetics. Lenalidomide maintenance had a favorable impact on PFS (median not reached vs. 27 months, p < 0.001), but no significant difference in OS was observed at this time point (p = 0.10).

In the whole study population, the viable (with 7-AAD) graft CD34+ cell count had no effect on PFS (Table S2) or OS in univariate analysis. However, in the subpopulation of patients mobilized with G-CSF only (n = 54), higher graft viable CD34+ cell count (>2.5 x 10⁶/kg, n = 14) was associated with inferior PFS (20 vs. 32 months, p = 0.049). This did not, however, translate into OS difference (p = 0.57). In the standard cytogenetic risk (SR) group (n = 95), higher graft CD34+ cell count (>2.5 x 10⁶/kg, n = 43, Table S3) was also linked with inferior PFS (28 vs. 46 months, p = 0.04), but there was no difference in the OS (p = 0.53) (Figure 1).
Higher graft CD34$^+$CD133$^+$CD38$^-$ cell count (>0.065 × 10$^6$/kg, $n = 59$, Table S4) did not significantly improve PFS (40 vs. 27 months, $p = 0.066$) or OS ($p = 0.081$) in the whole patient cohort. In the subgroup of chemomobilized patients ($n = 73$), however, CD34$^+$CD133$^+$ CD38$^-$ cell count >0.065 × 10$^6$/kg ($n = 40$) was
associated with a clearly better PFS (42 vs. 22 months, \( p = 0.021 \)) and an OS benefit (\( p = 0.025 \)) was also observed (Figure 2).

The graft CD3\(^+\) cell count had no impact on PFS. Very low CD3\(^+\) count (<20 \( \times 10^6 \)/kg, \( n = 16 \), Table S5) was associated with inferior OS in the whole study population.

**FIGURE 2** Progression-free survival (A) and overall survival (B) of myeloma patients mobilized with cyclophosphamide + G-CSF according to the graft CD34\(^+\)CD133\(^-\)CD38\(^-\) count. G-CSF, granulocyte colony-stimulating factor
(not reached vs. 47 months, \( p = 0.017 \)). In the non-HR subpopulation (\( n = 103 \)), graft CD3\(^+\) count >60 \times 10^6/kg, however, was linked with better OS (\( p = 0.042 \)). A higher graft CD3\(^+\)CD8\(^+\) cell count (> 15 \times 10^6/kg, \( n = 83 \), Table S6) was not linked with statistically significant difference in PFS (32 vs. 22 months, \( p = 0.082 \)), but an OS
advantage was observed ($p = 0.032$, Figure 3). Graft CD3+CD4+/CD3+CD8+ ratio had no effect on PFS or OS (data not shown).

In the whole study cohort, a low graft NK cell count (<2.5 $\times$ 10^6/kg, $n = 34$, Table S7) did not significantly impact PFS (25 vs. 30 months, $p = 0.155$) or OS.

**FIGURE 4** Progression-free (A) and overall survival (B) of the non-high-risk cytogenetics myeloma patients according to the graft NK cell content
TABLE 4  Associations between graft cellular components and progression-free survival and overall survival in univariate and multivariate cox regression analyses

| Graft cellular component (×10⁶/kg) | Progression-free survival | Overall survival |
|-----------------------------------|---------------------------|------------------|
|                                   | Univariate                | Multivariate     | Univariate                | Multivariate     |
|                                   | HR (95% CI) | p   | HR (95% CI) | p   | HR (95% CI) | p   |
| CD34⁺ cells with 7-AAD >2.5       | 1.480 (0.979–2.239) | 0.063 | 1.899 (1.162–3.102) | 0.010 | 0.808 (0.412–1.583) | 0.534 |
| CD34⁺CD133⁺CD38⁻ cells >0.0065    | 0.676 (0.444–1.029) | 0.068 | 0.501 (0.301–0.835) | 0.008 | 0.540 (0.267–1.091) | 0.086 |
| CD3⁻ cells <20                    | 1.544 (0.856–2.784) | 0.149 |                     |        | 2.545 (1.152–5.624) | 0.021 | 4.160 (1.758–9.842) | 0.001 |
| CD3⁻CD4⁺ cells >35                | 0.804 (0.527–1.226) | 0.310 |                     |        | 0.525 (0.267–1.034) | 0.062 |                     |        |
| CD3⁻CD8⁻ cells >15                | 0.683 (0.443–1.053) | 0.084 |                     |        | 0.486 (0.248–0.953) | 0.036 |                     |        |
| NK cells <2.5                     | 1.388 (0.882–2.184) | 0.157 | 1.799 (1.099–2.947) | 0.020 | 1.916 (0.968–3.795) | 0.062 |                     |        |
| Len maintenance                   | 0.254 (0.139–0.462) | <0.001 | 0.315 (0.158–0.625) | 0.001 | 0.459 (0.190–1.109) | 0.084 |                     |        |
| Mobilization method               |                     |        |                     |        |                     |        |                     |        |
| CY + G-CSF                        | 1                     |        |                     |        |                     |        |                     |        |
| G-CSF alone                       | 0.807 (0.527–1.236) | 0.323 |                     |        | 0.804 (0.397–1.628) | 0.545 |                     |        |
| Use of plerixafor                 | 1.013 (0.539–1.905) | 0.967 |                     |        | 0.918 (0.323–2.608) | 0.873 |                     |        |
| Cytogenetic risk                  |                       |        | 0.004               | 0.045 |                     |        |                     |        |
| SR                                | 1                     |        | 1.000              | 1.000 |                     |        |                     |        |
| HR                                | 2.214 (1.319–3.714) | 0.003 | 2.000 (1.154–3.466) | 0.013 | 4.163 (1.985–8.731) | <0.001 | 5.645 (2.528–12.609) | <0.001 |
| Unknown                           | 1.943 (0.985–3.797) | 0.055 | 1.275 (0.632–2.573) | 0.498 | 2.958 (1.090–8.023) | 0.033 | 3.311 (1.209–9.064) | 0.020 |
| Disease status 3 months after transplantation | 0.011 | 1.000 | 0.011 | 1.000 | 0.493 |
| sCR                               | 1                     |        |                     |        |                     |        |
| CR                                | 3.487 (1.057–11.499) | 0.040 | 1.803 (0.371–8.773) | 0.465 | 1.262 (0.268–5.952) | 0.769 |                     |        |
| VGPR                              | 5.090 (1.573–16.470) | 0.007 | 2.698 (0.570–12.760) | 0.211 | 2.177 (0.505–9.390) | 0.297 |                     |        |
| PR or worse                       | 6.299 (1.839–21.569) | 0.003 | 4.667 (0.982–22.180) | 0.053 | 1.983 (0.400–9.843) | 0.402 |                     |        |
| Gender                            |                       |        |                     |        |                     |        |
| Male                              | 1                     |        |                     |        |                     |        |
| Female                            | 0.980 (0.648–1.482) | 0.924 |                     |        | 1.284 (0.652–2.527) | 0.469 |                     |        |
| Age >60                           | 1.380 (0.839–2.270) | 0.205 |                     |        | 1.135 (0.514–2.506) | 0.755 |                     |        |

Note: The p values marked with bold are statistically significant (<0.05).
Abbreviations: CI, confidence interval; G-CSF, granulocyte colony-stimulating factor; HR, hazard ratio; SR, standard risk.
*Only variables significant in the final step of backward Cox regression are shown.
In the non-HR group, a low graft NK cell count was associated with worse OS ($p = 0.006$, Figure 4).

In multivariate analysis taking into account different graft cellular components, gender, age, risk group by cytogenetics, mobilization method, use of PLER,
lenalidomide maintenance and disease status 3 months after auto-SCT, higher graft CD34+CD133−CD38− count (>0.065 × 10^6/kg) and lenalidomide maintenance remained predictive of better PFS. In contrast, a high graft CD34+ count (>2.5 × 10^6/kg), low graft NK cell count (<2.5 × 10^6/kg), and high-risk cytogenetics predicted worse PFS. A very low graft CD3+ lymphocyte count (<20 × 10^6/kg) and non-SR cytogenetics were associated with worse OS in the multivariate model (Table 4).

In a subgroup of 22 patients (17%, Table S8), the infused graft contained ≤2.5 × 10^6/kg CD34+ cells and >0.065 × 10^6/kg CD34+CD133+CD38− cells. These graft components were linked with improved survival and could therefore be hypothesized to represent “optimal graft” in MM patients. The PFS of this subgroup was superior (NR vs. 27 months, p = 0.006) compared to the rest of the patient cohort but no statistically significant difference in OS was observed at this time point (p = 0.052) (Figure 5).

4 | DISCUSSION

This prospective multicenter study evaluated the impact of autograft cellular composition on post-transplant hematologic recovery, PFS, and OS in MM patients. A higher graft CD34+ cell count was associated with better PLT recovery. Surprisingly, higher CD34+ cell count predicted shorter PFS in the multivariate model. Of the other graft components, higher graft CD34+CD133−CD38− and CD3+CD8+ cell counts were beneficial, whereas a very low graft CD3+ cell count and low NK cell count correlated with an adverse outcome. These observations are of interest as, until now, scarce data are available regarding graft composition in MM patients.

The correlation of a higher infused graft CD34+ dose with faster PLT recovery and higher long-term PLT levels after auto-SCT have been described before. Klaus et al. have also shown a higher infused CD34+ count to correlate with faster leukocyte recovery. However, there are also previous studies suggesting that the infused CD34+ dose has no role in neutrophil recovery post-transplant. In our study, graft CD34+ counts had no effect on neutrophil engraftment or long-term neutrophil counts, but the use of G-CSF post-transplant predicted faster neutrophil engraftment in multivariate analysis.

There are some retrospective studies suggesting that the infused graft CD34+ cell dose has no effect on survival in MM patients. In contrast, Toor et al. have demonstrated higher amount of infused CD34+ cells to predict better PFS and OS after auto-SCT. Also, O’Shea et al. have shown that graft CD34+ count >3.5 × 10^6/kg CD34+ cells correlates with better OS. In addition, poor mobilization has predicted shorter PFS and OS in some studies. In our study, a higher graft CD34+ cell count was associated with shorter PFS with no effect on OS. A potential explanation to this PFS difference might be mobilization of malignant plasma cells into the graft, which has previously been linked with shortened PFS and OS, although in some studies this connection has not been detected. CD34+ cell selection has been able to decrease the amount of tumor cells in the grafts but, however, not impacted PFS or OS in previous studies. We did not measure clonal plasma cells in the grafts in the GOA study, but the majority of the patients had achieved at least a very good partial response at the time of mobilization of blood grafts.

A higher CD34+CD133−CD38− cell count (>0.065 × 10^6/kg) in the graft predicted better PFS in multivariate analysis in this study, and in the subgroup of chemomobilized patients this cell compartment was associated with better PFS and also OS. This association has not been described previously in MM patients. Henon et al. have suggested a minimum graft content of 0.05 × 10^6/kg CD34+CD133−CD38− cells to ensure timely and durable trilineage hematopoietic reconstitution. A higher graft CD34+CD133−CD38− cell count has been shown to correlate with more rapid immune recovery after auto-SCT in NHL patients. Respectively, also in MM patients, more rapid immune recovery has been linked with better outcome. This might also be an explanation for our finding although immune recovery was unfortunately not studied in GOA study in detail.

Porrata et al. have previously demonstrated that an infused graft total lymphocyte count >500 × 10^6/kg was linked with better PFS and OS in MM patients. In addition, Hiwase et al. have shown infused total lymphocyte dose >200 × 10^6/kg to be associated with improved lymphocyte recovery at day +30 after graft infusion, which, in turn, predicted better PFS and OS. Also, conflicting results have been published in this topic. In our study, a very low graft CD3+ count (<20 × 10^6/kg, n = 16) was linked with worse OS. In the non-HR patient subgroup, an OS advantage was observed also with graft CD3+ >60 × 10^6/kg. A higher infused graft lymphocyte count is known to correlate with more rapid immune recovery after auto-SCT. The possible explanation to the observed survival benefit might be the complex antitumor effects mediated by these immune cells.

Schmidmeier et al. have previously demonstrated a higher autograft CD3+CD4+/CD3+CD8+ ratio and higher graft CD4+ count to correlate with prolonged event-free survival in MM patients. In this study, no such correlation was observed. However, a higher graft CD8+ cell count seemed to be beneficial in terms of
OS. The immune reconstitution after auto-SCT, although not addressed in this study, has been shown to be important for disease control in MM patients.\textsuperscript{44}

The graft NK cell compartment is of special interest because in MM patients faster NK cell recovery has been linked with improved outcome after auto-SCT.\textsuperscript{15} Dysfunction of NK cells has been associated with disease progression,\textsuperscript{45} and a lower NK cell count post-transplant has correlated with disease relapse after auto-SCT.\textsuperscript{44} In this study, graft NK cell count >2.5 \times 10^{6}/kg predicted better PFS in a multivariate model. There are no previous publications linking graft NK cell count with improved outcome in MM patients. NK cells may vary in terms of immunophenotype and function.\textsuperscript{46} In the future, more precise immunophenotyping of the graft NK cells in regard to outcome after auto-SCT should be performed. The NK cell compartment might well be a critical factor in addition to disease biology in the efficacy of post-transplant strategies including lenalidomide maintenance.

These results should be interpreted with caution, as there are some limitations in this study. First, the differences in the mobilization method used lead to significant variation in graft cellular composition. Second, pre- and post-transplant treatment regimens used differed to some extent and this is likely to affect the outcome of the patients. Third, the categorization of continuous variables leads to inevitable loss of information. Although subgroup analyses were performed and a multivariate model was used to determine the significant graft cellular components and cutoffs in regard to outcome, some information is likely to be lost. Finally, although some graft components remained significant in terms of PFS and OS in the multivariate model, causality cannot be evaluated with this study design. On the other hand, the prospective multicenter setting, a reasonable number of patients, centralized graft analysis and a long follow-up are among the obvious strengths of this study.

To conclude, in this prospective multicenter study, we observed survival differences in MM patients according to graft cellular composition. The associations between higher graft CD34\textsuperscript{+}CD133\textsuperscript{+}CD38\textsuperscript{−} and NK cell counts and improved outcome after auto-SCT have not been described earlier. The negative correlation between graft CD34\textsuperscript{+} count and PFS is a quite provocative finding, which raises questions about the optimal graft CD34\textsuperscript{+} dose in terms of outcome. Validation of these findings in an independent patient cohort or in a randomized study setting aiming for desired graft composition in the future is essential. This study suggests that the autograft cellular composition beyond the CD34\textsuperscript{+} cell count might be of importance.

**ACKNOWLEDGMENTS**

The GOA study was supported by North Savo Hospital District VTR and EVO Funds and also Sanofi Genzyme. Dr Turunen is grateful for the grants provided by North Savo Hospital District Research Fund, Blood Disease Research Foundation, The Finnish Medical Foundation, Cancer Fund of North Savo, and the Finnish Society of Hematology. We thank Antti Ropponen for the flow cytometry analyses and M.Sc. Tuomas Selander for the statistical support.

**CONFLICT OF INTEREST**

Dr RS has received Celgene Research Funding for FMG-MM02 study, Amgen, BMS, and Takeda Research funding, compensation as a member of the Scientific Advisory Boards of Celgene, Amgen, Janssen-Cilag, Takeda and consultancy fees from Amgen, Celgene, Janssen-Cilag, and Sanofi. Dr AP reports honoraria from Behring and Abbvie and has participated in Scientific Advisory Board meetings organized by Abbvie and Takeda. Dr JV has participated in Scientific Advisory Boards organized by Amgen and Janssen-Cilag and has also received consultancy fees from Amgen, Sanofi, and Janssen-Cilag. Dr TS has participated in the Scientific Advisory Boards of Roche, Amgen, Novartis, and Pfizer and received consultancy fees from Amgen. Dr MP has received consultancy fees from Janssen-Cilag, Amgen, Takeda, Celgene, and Sanofi and has participated in the Scientific Advisory Boards organized by Amgen, Janssen-Cilag, Takeda, Celgene, and Sanofi. Dr TK has received consultancy fees from Sanofi-Genzyme, BMS, Sanofi, Celgene, Roche, Amgen, Janssen-Cilag, Pfizer, Leo-Pharma, Sobi, MSD, Takeda, Bayer, Novo Nordisk, and Boehringer-Ingelheim, has received grants from Novartis and AstraZeneca and has participated in the Scientific Advisory Board organized by Celgene. Dr MP has received honoraria from Amgen, Novartis, and Pfizer and participated in Scientific Advisory Boards organized by Pfizer. Dr EJ has participated in the Scientific Advisory Boards of Amgen, Takeda, TEVA, and Sanofi. Dr VV reports consultancy fees from Abbvie, Amgen, Celgene, Janssen-Cilag, Roche, and Sanofi. AT, MS, KP, AS, ERS, PM, and PJ have disclosed no conflicts of interest.

**ORCID**

Antti Turunen [https://orcid.org/0000-0002-3693-2956](https://orcid.org/0000-0002-3693-2956)

Anu Partanen [https://orcid.org/0000-0002-5634-2582](https://orcid.org/0000-0002-5634-2582)

**REFERENCES**

1. Passweg JR, Baldomero H, Chabannon C, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant. 2020;55:1604–13.
2. Attal M, Lauwers-Cancès V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

3. Dhakal B, Szabo A, Chhabra S, Hamadani M, D’Souza A, Usmani SZ, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4:343–50.

4. Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulo MA. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929.

5. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035–42.

6. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15:718–23.

7. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–55.

8. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43:619–25.

9. Valtola J, Silvennoinen R, Popponen A, Siitonen T, Siilmy M, Sankelo M, et al. Blood graft cellular composition and post-transplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Transfusion. 2016;56:1394–401.

10. Valtola J, Silvennoinen R, Popponen A, Siitonen T, Siilmy M, Sankelo M, et al. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study. Leuk Lymphoma. 2019;60:2781–91.

11. Toor AA, Ayers J, Strupeck J, Parthasarathy M, Creech S, Rodriguez T, et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol. 2004;124:769–76.

12. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2004;18:1085–92.

13. Hiwase DK, Hiwase S, Bailey M, Bolland G, Schwager AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14:116–24.

14. Schmidmaier R, Oversohl N, Schnabel B, Straka C, Emmerich B. Helper T cells (CD3+CD4+) within the autologous peripheral blood stem cell graft positively correlate with event free survival of multiple myeloma patients. Exp Oncol. 2008;30:240–3.

15. Rueff J, Medinger M, Heim D, Passweg J, Stern M. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant. 2014;20:896–9.

16. Silvennoinen R, Anttila P, Siilmy M, Lundan T, Heiskanen J, Siitonen TM, et al. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant. 2016;51:372–6.

17. Luoma S, Anttila P, Siilmy M, Lundan T, Heiskanen J, Siitonen T, et al. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group. Ann Hematol. 2019;98:2781–91.

18. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.

19. Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy. 2003;5:55–65.

20. Turunen A, Partanen A, Valtola J, Popponen A, Siitonen T, Kuittinen O, et al. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin’s lymphoma patients: results of the prospective multicenter GOA study. Transfusion. 2020;60:1519–28.

21. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588–96.

22. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000;18:1360–77.

23. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:967–72.

24. Stiff PJ, Micalef I, Nademane AP, Stadmayer EA, Maziarz RT, Bolwell BJ, et al. Transplanted CD34(+) cell dose is associated with long-term plateau count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant. 2011;17:1146–53.

25. Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol. 2007;78:21–8.

26. Ungerstedt JS, Watz E, Uttervall K, Johansson BM, Wahlin BE, Nisnman P, et al. Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. Med Oncol. 2012;29:2191–9.
27. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant. 2003;31:163–70.

28. O’Shea D, Giles C, Terpos E, Perez J, Politou M, Sana V, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 2006;37:731–7.

29. Moreb JS, Salmasinia D, Hsu J, et al. Long-term outcome after autologous stem cell transplantation with adequate peripheral blood stem cell mobilization using plerixafor and G-CSF in poor mobilizer lymphoma and myeloma patients. Adv Hematol. 2011;2011:517561–8.

30. Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, et al. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autograft transplantation. Bone Marrow Transplant. 2015;50:673–8.

31. Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V, Nannetti A, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood. 1996;87:1625–34.

32. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 1997;19:337–42.

33. Vogel W, Kopp H, Kanz L, et al. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol. 2005;131:214–8.

34. Kopp HG, Yildirim S, Weisel KC, Kanz L, Vogel W. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol. 2009;135:637–42.

35. Ho J, Yang L, Banihaneshi B, Martin L, Halpenny M, Atkins H, et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2009;43:223–8.

36. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Puriﬁcation of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771–9.

37. Bourhis J, Bouko Y, Koscielny S, et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica. 2007;92:1083–90.

38. Henon P, Sovalat H, Becker M, et al. Primordial role of CD34+ 38-cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation. Br J Haematol. 1998;103:568–81.

39. Valtola J, Varmavuo V, Ropponen A, Kuitinen O, Kuitinen H, et al. Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance. Leuk Lymphoma. 2016;57:2025–32.

40. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–85.

41. Kim H, Sohn H, Kim S, et al. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2006;37:1037–42.

42. Percy LA, Moore SE, Qian W, Dorman J, Rabin N, Watts M, et al. Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2012;157:494–6.

43. Porrata LF. Autologous graft-versus-tumor effect: reality or fiction? Adv Hematol. 2016;2016:1–8. https://doi.org/10.1155/2016/5385972.

44. Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4:61–71.

45. Godfrey J, Benson DM. The role of natural killer cells in immunity against multiple myeloma. Leukemia Lymphoma. 2012;53:1666–76.

46. Poznanski SM, Ashkar AA. What defines NK cell functional fate: phenotype or metabolism? Front Immunol. 2019;10:1414.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.